This site is intended for healthcare professionals

Sanofi and GSK announced the initiation of a new phase II study to select the most appropriate antigen dosage for phase III evaluation of their adjuvanted recombinant protein COVID-19 vaccine.

Read time: 1 mins
Last updated:28th Jun 2021
Published:23rd Feb 2021
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest